May Health Appoints Ex-Organon Leader to Revolutionize PCOS Treatment with Ovarian Rebalancing™
- Colby Holtshouse, with experience from Organon, is appointed President and CEO of May Health to enhance women's health leadership.
- May Health's Ovarian Rebalancing™ technology aims to significantly advance treatment options for PCOS-related infertility.
- The REBALANCE study is crucial for May Health's innovative therapy's marketing authorization, promising impactful outcomes for women globally.
Transformative Leadership at May Health: A New Era for PCOS Treatment
May Health, a clinical-stage medical device company with dual bases in Paris and California, is making significant strides in the evaluation of its innovative Ovarian Rebalancing™ technology aimed at addressing Polycystic Ovary Syndrome (PCOS). This condition affects approximately 10% of women and is a leading cause of infertility. Recently, the company has appointed Colby Holtshouse as President and CEO, a move that signals a strategic shift towards enhancing leadership in women's health. Holtshouse possesses a wealth of experience from her previous roles at Organon, Alydia Health, and Pelvalon, making her the ideal candidate to navigate the complexities of the women's health landscape and drive the company toward its ambitious goals.
Under Holtshouse’s leadership, May Health is focusing on the REBALANCE study, an investigational device exemption (IDE) clinical trial designed to support marketing authorization for its Ovarian Rebalancing procedure. This innovative treatment offers a one-time, ultrasound-guided transvaginal ablation that utilizes radio frequency energy to target and eliminate excess androgen-producing ovarian tissue. By restoring ovulation in women who do not respond to traditional oral medications, the procedure aims to establish regular ovulatory menstrual cycles with same-day recovery and minimal disruption to patients' daily activities. The potential for this technology to provide a new avenue for those suffering from PCOS-related infertility is substantial, indicating a much-needed advancement in therapeutic options.
Dr. Robert Auerbach, Chairman of May Health, expresses optimism regarding Holtshouse’s appointment, especially given the ongoing clinical trials. The timing of this leadership transition coincides with critical phases of research and development, allowing for a seamless continuation of efforts to bring this innovative therapy to market. Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, echoes this sentiment, emphasizing the transformative potential of May Health’s approach to treating infertility that stems from PCOS. As the company prepares for commercialization, the advancements made under Holtshouse's guidance are poised to impact millions of women globally, filling a significant gap in the current treatment landscape.
May Health's commitment to improving women's health through innovative technologies positions it as a leader in the field. As the company progresses with clinical trials and prepares for potential market entry, the strategic leadership of Holtshouse and the pioneering nature of the Ovarian Rebalancing procedure signal a hopeful future for women affected by PCOS. The importance of addressing this condition cannot be overstated, as it not only affects reproductive health but also has far-reaching implications for overall well-being.
In addition to the leadership shift, the REBALANCE study serves as a pivotal point for May Health, marking a critical phase in the development of its groundbreaking technology. The company is poised to redefine treatment paradigms for PCOS and looks forward to the potential impact of its innovative solutions on women's health globally.
